Physician profile
Michael Merkey
NPI 1568555886
$5,454.15
in general payments reported to CMS, 2019-2025
46 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,124 · 2020: $447 · 2021: $337 · 2022: $923 · 2023: $896 · 2024: $577 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,551 · Education: $71.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.51 |
| Education | $71.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $626.67 | 2021-2024 | |
| Ucb, INC. | $472.09 | 2019-2024 | Briviact, Fintepla |
| Teva Pharmaceuticals USA, INC. | $376.56 | 2019-2023 | Austedo Xr |
| Amgen INC. | $346.24 | 2019-2023 | Aimovig |
| Supernus Pharmaceuticals, INC. | $264.97 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $240.29 | 2019 | |
| Alexion Pharmaceuticals, INC. | $237.87 | 2019-2024 | Ultomiris |
| Acadia Pharmaceuticals INC | $233.90 | 2019-2024 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $224.00 | 2019-2024 | |
| Allergan, INC. | $198.15 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $195.22 | 2019-2024 | Rytary |
| Tg Therapeutics, INC. | $174.09 | 2024-2025 | |
| Lilly USA, LLC | $164.50 | 2019-2023 | Reyvow, Emgality |
| Argenx US, INC. | $163.99 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $160.11 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Merkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.